Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
We send one confirmation email first. Only emails about CDIO, unsubscribe in one click. Privacy
| Drug | Indication | Most advanced trial | Status |
|---|---|---|---|
| Acetylsalicylic acid ASA | SCAD | Phase 4 · NCT07683923 | Not yet recruiting |
| Arylsulfatase A | SCAD | Phase 4 · NCT07683923 | Not yet recruiting |
| Sodium-GLucose coTransporter-2 inhibitor | Sodium-GLucose coTransporter-2 Inhibitors | N/A · NCT05344963 | Completed |
Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it
CDIO holds $5.6M in cash and short-term investments and burns about $1.4M/quarter from operations, an estimated runway of 11.8 months at that rate (BioRadar estimate, not company guidance).
Dilution pressure: 75 · High
Recent financing filings on SEC EDGAR:
Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when CDIO files for a raise →
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for CDIO and every other ticker you follow. Card required, cancel anytime.
Start 7-day free trial →